Miracor Medical SA, an Awans, Belgium-based provider of innovative solutions for the treatment of severe cardiac diseases, closed a €24M Series E round of financing.
The round was led by a new corporate strategic investor joined by co-investor Yonghua. Current investors Earlybird, Noshaq, Quest for Growth, SFPI-FPIM, SRIW and another corporate strategic investor also supported this financing.
The funds will be used to advance the PiCSO clinical study program, which will recruit and randomize up to 750 patients in three studies in Europe and the USA. Additionally, commercialization will start in Europe.